#sparsentan — Public Fediverse posts

On the topic of flozins - no flozins allowed during double blind phase

🤷🏽‍♂️

My 2 cents: I am not using #Sparsentan - clearly flozins cheaper, with CV benefit. Sparsentan might reduce proteinuria but in long term cause CV harm.

Should we use them in combo? Maybe

7/7

On the topic of flozins - no flozins allowed during double blind phase

🤷🏽‍♂️

My 2 cents: I am not using #Sparsentan - clearly flozins cheaper, with CV benefit. Sparsentan might reduce proteinuria but in long term cause CV harm.

Should we use them in combo? Maybe

7/7

This is the methods section of interest - RASi ‘optimized’ ie the maximum tolerated dose had to be at least 50% of max (😏) and BP < 150/100

Note biopsy timing doesn’t matter

Note exclusion for heart failure (Endothelin antagonist specific issue!)

This is the interim result for FDA approval (obtained) of 36 week follow up, final follow up is 114 weeks, plus an observational period

#Sparsentan #IgANephropathy

2/

Adverse effects of interest - as expected more sodium retention and even more AKI (!) with #Sparsentan

The clinical kidney outcomes were less with Sparsentan (7 vs 13) but this is where I would like to see longer term effects of that sodium retention with Sparsentan. So let’s wait and see for final results I say

5/

Headline result from the #Sparsentan PROTECT trial in #IgANephropathy in #Lancet https://authors.elsevier.com/c/1grIl_3CjG8WAP

1/🧵

Full text link via @Rheault_m

Big proteinuria reduction:

Adverse effects of interest - as expected more sodium retention and even more AKI (!) with #Sparsentan

The clinical kidney outcomes were less with Sparsentan (7 vs 13) but this is where I would like to see longer term effects of that sodium retention with Sparsentan. So let’s wait and see for final results I say

5/

This is the methods section of interest - RASi ‘optimized’ ie the maximum tolerated dose had to be at least 50% of max (😏) and BP < 150/100

Note biopsy timing doesn’t matter

Note exclusion for heart failure (Endothelin antagonist specific issue!)

This is the interim result for FDA approval (obtained) of 36 week follow up, final follow up is 114 weeks, plus an observational period

#Sparsentan #IgANephropathy

2/

Headline result from the #Sparsentan PROTECT trial in #IgANephropathy in #Lancet https://authors.elsevier.com/c/1grIl_3CjG8WAP

1/🧵

Full text link via @Rheault_m

Big proteinuria reduction: